Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 3 September 2018, 14:50 HKT/SGT
Share:
    

Source: Eisai
Eisai Receives Approval for Partial Label Change for Vascular Embolization Device DC Bead

TOKYO, Sept 3, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that it has received approval for a partial label change for the vascular embolization device DC Bead (specially controlled medical device) in Japan. The product is to be used for transcatheter arterial embolization in patients with hypervascular tumors (excluding uterine fibroids).

In real-world clinical settings, it was found that DC Bead was not being used in the treatment of uterine fibroids and arteriovenous malformations. Following confirmation at related academic associations and subsequent consultation with the regulatory authority, an application for a partial label change for the relevant indication was submitted, upon which this approval is based.

With the partial label change for DC Bead, Eisai is striving to ensure that accurate information is provided to healthcare professionals.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Sept 3, 2018 14:50 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Oct 19, 2018 11:18 HKT/SGT
Eisai: Discovery of Candidate Compound as Potential Treatment for Parkinson's Disease Using iPS Cells
Oct 18, 2018 08:03 HKT/SGT
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference
Oct 17, 2018 08:51 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Oct 16, 2018 17:38 HKT/SGT
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Latin America With Eurofarma
Oct 12, 2018 13:48 HKT/SGT
Eisai's New Drug Application for Perampanel for Adjunctive Treatment of Partial Onset Seizures Accepted in China
Oct 10, 2018 14:35 HKT/SGT
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2018 Congress
Oct 5, 2018 09:30 HKT/SGT
New Data on Effect of Anti-Obesity Agent BELVIQ on Prevention and Remission of Type 2 Diabetes Presented at The European Association for the Study of Diabetes and Published in The Lancet
Oct 1, 2018 07:48 HKT/SGT
Eisai's Fycompa Newly Approved by U.S. FDA as Treatment for Partial-Onset Seizures in Pediatric Patients with Epilepsy
Sept 5, 2018 14:28 HKT/SGT
Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC
Aug 30, 2018 09:36 HKT/SGT
Eisai's LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: